TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25436319

Group type: EXPERIMENTAL
Intervention: Combined Therapy (HAIC plus systemic chemotherapy)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Monotherapy (systemic chemotherapy alone)
Number of subjects: 106
Study: 21086017

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide therapy for 4 years
Number of subjects: 5993

Group type: COMPARATOR
Intervention: Routine COPD care (RC)
Number of subjects: 5993
Study: 20380708

Group type: EXPERIMENTAL
Intervention: Activ-L Artificial Disc
Number of subjects: 414

Group type: COMPARATOR
Intervention: Charité Artificial Disc [DePuy Spine] or ProDisc-L Total Disc Replacement [Synthes Spine]
Number of subjects: 414
Study: 18166745

Group type: EXPERIMENTAL
Intervention: LMA-Proseal (PLMA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: LMA-Classic (CLMA)
Number of subjects: 51
Study: 16105333

Group type: COMPARATOR
Intervention: Diclofenac 75 mg intramuscularly (i.m.) 30 min before the procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg i.m. 30 min before the procedure, together with local infiltration of the cervix with lignocaine 1% (10 mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg i.m. 30 min before the procedure together with local infiltration of the cervix with lignocaine 1% (10 mL) and paracervical block with lignocaine 1% (5 mL)
Number of subjects: 0
Study: 11788216

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1-mg nicotine)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cigarette smoke (1-mg nicotine, 12 mg tar)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (Nitroglycerin-induced dilation)
Number of subjects: 16
Study: 10037314

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM) administered continuously at 1.5 mg/kg per hour from the beginning of anesthesia until the third postoperative day (preop GM group)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gabexate mesilate (GM) administered continuously at 1.5 mg/kg per hour from the end of surgery and for the same postoperative period (postop GM group)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM) administered in the preop GM group
Number of subjects: 11
Study: 7565999

Group type: EXPERIMENTAL
Intervention: Postprandial monitoring
Number of subjects: 66

Group type: COMPARATOR
Intervention: Preprandial monitoring
Number of subjects: 66
Study: 2309827

Group type: EXPERIMENTAL
Intervention: Continuous ethinyl estradiol and norethindrone acetate (various doses)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conjugated estrogens 0.625 mg and medroxyprogesterone acetate 10 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 77
Study: 48835

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol and insulin
Number of subjects: 14
Study: 31139687

Group type: EXPERIMENTAL
Intervention: Intensive exercise regimen (IER, five sessions/week)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual exercise regimen (UER, two sessions/week)
Number of subjects: 65
Study: 29118975

Group type: EXPERIMENTAL
Intervention: Self-adhering flowable resin composite (Vertise™Flow)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Total-etch resin composite (Te-Econom Plus)
Number of subjects: 16
Study: 25213161

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for weeks 1-3 of each 4-week cycle
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 760
Study: 24187864

Group type: EXPERIMENTAL
Intervention: BHY group (BHY instant granules, 6 g, twice per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (piracetam, 0.8 g, 3 times per day)
Number of subjects: 60
Study: 22048559

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral stress management intervention (Coping With Cancer Workbook)
Number of subjects: 123
Study: 19210020

Group type: COMPARATOR
Intervention: Selection of reciprocal friends
Number of subjects: 1886

Group type: COMPARATOR
Intervention: Selection of nonreciprocal friends
Number of subjects: 1886

Group type: COMPARATOR
Intervention: Influence from nonreciprocal friends
Number of subjects: 1886

Group type: COMPARATOR
Intervention: Influence from parents
Number of subjects: 1886

Group type: COMPARATOR
Intervention: Influence from siblings
Number of subjects: 1886
Study: 16420200

Group type: EXPERIMENTAL
Intervention: Simvastatin up to 20 mg/d for 15 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 80
Study: 15612606

Group type: EXPERIMENTAL
Intervention: Large win on the 1st play
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Large win on the 5th play
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2 small wins on the 2nd and 5th plays
Number of subjects: 4

Group type: COMPARATOR
Intervention: No wins
Number of subjects: 4
Study: 11242737

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum regimen
Number of subjects: 35

Group type: COMPARATOR
Intervention: Teachers' acceptance of the chewing program
Number of subjects: 35
Study: 10678020

Group type: EXPERIMENTAL
Intervention: SPLPV (splenectomy plus ligation of pericardial vein)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Shunt
Number of subjects: 26
Study: 7698862

Group type: EXPERIMENTAL
Intervention: Bioabsorbable osteosynthetic implants of ultra high strength poly-L-lactide (PLLA)
Number of subjects: 143
Study: 3556192

Group type: EXPERIMENTAL
Intervention: Buccal nifedipine 20 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 29239148

Group type: EXPERIMENTAL
Intervention: AutoTIVA
Number of subjects: 132

Group type: COMPARATOR
Intervention: DES
Number of subjects: 132

Group type: COMPARATOR
Intervention: SEVO
Number of subjects: 132

Group type: COMPARATOR
Intervention: ManualTIVA
Number of subjects: 132
Study: 27110823

Group type: EXPERIMENTAL
Intervention: Synthetic unimolecular pentavalent carbohydrate vaccine (Globo‐H, GM2, sTn, TF, and Tn) conjugated to keyhole limpet haemocyanin (KLH) mixed with immunological adjuvant QS‐21 at doses of 25, 50, and 100 mcg.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 26211161

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal liquid diet
Number of subjects: 0
Study: 23687780

Group type: EXPERIMENTAL
Intervention: Nurse-led case management program (monthly telephone calls, motivational interviewing for lifestyle change, home BP monitoring, dosettes for medication administration)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 20212061

Group type: EXPERIMENTAL
Intervention: Trospium hydrochloride
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 18197453

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 201

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 201
Study: 16423519

Group type: EXPERIMENTAL
Intervention: St. John's Wort (PM235) - lower dose (0.12% hypericine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: St. John's Wort (PM235) - higher dose (0.18% hypericine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: St. John's Wort (PM235) - pooled high and low doses
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 14625664

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐EDDA/HYNIC‐TOC scintigraphy
Number of subjects: 54

Group type: COMPARATOR
Intervention: (18)F‐FDG PET
Number of subjects: 54
Study: 11727665

Group type: EXPERIMENTAL
Intervention: GTN patches (0.4‐0.8 mg/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: fenoterol per infusionem (60‐120 micrograms/h)
Number of subjects: 50
Study: 9228496

Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol (0.050 mg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Continuous oral conjugated estrogens (0.625 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 51
Study: 8425628

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intratubal and intrauterine insemination (ITI/IUI)
Number of subjects: 41
Study: 3592731

Group type: EXPERIMENTAL
Intervention: Silicone dummies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latex dummies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dummy carriage
Number of subjects: 0
Study: 30658096

Group type: EXPERIMENTAL
Intervention: rIPC treatment (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (n=8)
Number of subjects: 16
Study: 28738397

Group type: EXPERIMENTAL
Intervention: Self-management education with telephone follow-up
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 64
Study: 26386764

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg/day)
Number of subjects: 302
Study: 23988179

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus cognitive-coping therapy (PCCT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 145
Study: 20607405

Group type: EXPERIMENTAL
Intervention: Pantoprazole high dose (1.2 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pantoprazole low dose (0.6 mg/kg)
Number of subjects: 45
Study: 19409119

Group type: EXPERIMENTAL
Intervention: 2-suture technique (2 Vicryl 2-0 stitches at 3- and 9-o'clock positions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6-suture technique (6 Vicryl 2-0 stitches at 2-, 4-, 6-, 8-, 10-, and 12-o'clock positions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2-suture technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6-suture technique
Number of subjects: 100
Study: 17256445

Group type: EXPERIMENTAL
Intervention: locally infused trapidil (5 ‐ 400 microg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: norepinephrine (11 ‐ 1,000 ng/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: dinoprost (90 ‐ 5,600 ng/min)
Number of subjects: 10
Study: 15097237

Group type: COMPARATOR
Intervention: Flow-mediated response
Number of subjects: 195

Group type: COMPARATOR
Intervention: Glyceryl trinitrate response
Number of subjects: 195
Study: 11125233

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride-impregnated central venous catheter (CVC) (n = 25)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard triple-lumen central venous catheter (CVC) (n = 25)
Number of subjects: 70
Study: 9728897

Group type: EXPERIMENTAL
Intervention: Clofibrate (2 gm/day over 1 week)
Number of subjects: 12
Study: 7828491

Group type: EXPERIMENTAL
Intervention: B‐I+(VT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Roux(B‐II)+VT
Number of subjects: 26
Study: 3125025

Group type: EXPERIMENTAL
Intervention: misoprostol 400 micrograms bid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg and misoprostol 400 micrograms bid
Number of subjects: 16

Group type: COMPARATOR
Intervention: untreated patients
Number of subjects: 16
Study: 31183593

Group type: EXPERIMENTAL
Intervention: CBT-based paraprofessional training program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list (WL) group
Number of subjects: 40
Study: 29494423

Group type: EXPERIMENTAL
Intervention: Genotype-guided pharmacogenetics guided (PHG) warfarin dosing
Number of subjects: 205

Group type: COMPARATOR
Intervention: Clinically guided non pharmacogenetics guided (NPHG) warfarin dosing
Number of subjects: 205
Study: 27016718

Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser at 11.2 mJ per laser channel with 1% density, MAL 160 mg/g, 180 min incubation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser at densities of 1%, 2%, 5%, 10%, and 15%
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ablative fractional Er:YAG laser at 5% density and median incubation time of 80 min MAL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MAL 80 and 160 mg/g
Number of subjects: 11
Study: 24484545

Group type: EXPERIMENTAL
Intervention: Staff supervision
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Equipment
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Staff + Equipment
Number of subjects: 393
Study: 23852294

Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (PHF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Highly active antiretroviral treatment (HAART)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PHF-to-HAART arm
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PHF arm at 1 month
Number of subjects: 63
Study: 20186439

Group type: COMPARATOR
Intervention: Lidocaine 1 mg kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg kg(‐1) with remifentanil 1 microg kg(‐1) min(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rocuronium 1 mg kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol 2‐2.5 mg kg(‐1)
Number of subjects: 30
Study: 18243569

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei DN‐114 001 at 10(8) CFU/g
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 15891924

Group type: EXPERIMENTAL
Intervention: Midazolam (0.6 mg/kg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (25 mg/kg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 53
Study: 12965939

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study: 10807891

Group type: EXPERIMENTAL
Intervention: Variable stiffness colonoscope (VS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Olympus CF200HL (200HL)
Number of subjects: 100
Study: 9273207

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4+CD8+ lymphocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 1518258

Group type: EXPERIMENTAL
Intervention: Low-risk (LR) protocol with leukocytopenic episodes
Number of subjects: 213

Group type: COMPARATOR
Intervention: Low-risk (LR) protocol without leukocytopenic episodes
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mean relative dose greater than 0.9
Number of subjects: 213
Study: 6542606

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 0
Study: 30176897

Group type: EXPERIMENTAL
Intervention: High dose primaquine (0.5 mg base/kg body weight) for 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional dose primaquine (0.25 mg/kg) for 14 days
Number of subjects: 50
Study: 27629871

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 g daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 24851986

Group type: EXPERIMENTAL
Intervention: Computerized decision aid (DA)
Number of subjects: 0
Study: 22971528

Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heating pad application
Number of subjects: 40
Study: 19844770

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (PR) in Group A (Outerbridge Grades I, II, III)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (PR) in Group B (Outerbridge Grade IV)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Comparison of risk between Group A and Group B
Number of subjects: 500
Study: 18580611

Group type: EXPERIMENTAL
Intervention: Four injections of ALVAC-HIV vaccine (vCP1452) at weeks 0, 4, 8, 20
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Three injections of ALVAC-HIV vaccine (vCP1452) at weeks 4, 8, 20
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Four injections of ALVAC-HIV vaccine (vCP1452)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Three injections of ALVAC-HIV vaccine (vCP1452)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Immunization (both three and four injections)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CD4 nadir
Number of subjects: 65
Study: 15709997

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 999

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 999
Study: 12660570

Group type: EXPERIMENTAL
Intervention: YOn (eyes open in the dark)
Number of subjects: 15

Group type: COMPARATOR
Intervention: YF (normal eyelid closure)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: YFF (forcibly closed eyelids)
Number of subjects: 15
Study: 10778521

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg + nimesulide 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 10
Study: 9345406

Group type: EXPERIMENTAL
Intervention: High-dose Betaseron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose Betaseron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1828683

Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg x 3 daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7055434

Group type: EXPERIMENTAL
Intervention: Intraoperative peritoneal irrigation (group 2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both intraoperative and postoperative peritoneal irrigation (group 3)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No peritoneal irrigation (group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Survivors of all groups
Number of subjects: 44
Study: 31776820

Group type: EXPERIMENTAL
Intervention: Intraoperative iodine (5 mL of 0.25% povidone-iodine applied at 2 stages)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Preoperative topical antibiotics (administered 3 days before surgery)
Number of subjects: 102
Study: 31898677

Group type: EXPERIMENTAL
Intervention: Resistant starch (30 gm daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Digestible starch (control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 30335422

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy for PTSD
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral therapies for OCD
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy in a naturalistic setting
Number of subjects: 260
Study: 26888988

Group type: EXPERIMENTAL
Intervention: Lower 10-second heart rate variability (HRV)
Number of subjects: 3583

Group type: COMPARATOR
Intervention: Higher 10-second heart rate variability (HRV)
Number of subjects: 3583
Study: 25825091

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) mouth rinse used twice daily for one week
Number of subjects: 18

Group type: COMPARATOR
Intervention: Mouth rinse without CHX (control group)
Number of subjects: 18
Study: 21593784

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no pravastatin)
Number of subjects: 0
Study: 18820280

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 143

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 143
Study: 17937843

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg first dose, followed by two doses of 5 mg/kg each at 24 hr intervals)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral indomethacin (0.2 mg/kg at 24 hr intervals)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral indomethacin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 36
Study: 15200437

Group type: EXPERIMENTAL
Intervention: 50 mg of iron (III) sucrose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 mg of iron (III) sucrose
Number of subjects: 6
Study: 17355727

Group type: EXPERIMENTAL
Intervention: Perception of female rape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of male rape
Number of subjects: 0
Study: 10619802

Group type: EXPERIMENTAL
Intervention: Intensivists with consensus training
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intensivists without consensus training
Number of subjects: 99
Study: 8796137

Group type: EXPERIMENTAL
Intervention: 20 mg fenfluramine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 60 mg fenfluramine
Number of subjects: 6

Group type: COMPARATOR
Intervention: CRH injection
Number of subjects: 6
Study: 1620826

Group type: EXPERIMENTAL
Intervention: recombinant human-tissue-type plasminogen activator (rTPA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: rTPA plus heparin
Number of subjects: 62

Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: rTPA with or without heparin
Number of subjects: 62
Study: 6538427

Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg) with phenazone (15 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg) with phenazone (15 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cimetidine and metronidazole
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 9
Study: 30853816

Group type: EXPERIMENTAL
Intervention: Extended venous thromboembolism prophylaxis (vte) with low molecular weight heparin (lmwh)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No extended venous thromboembolism prophylaxis
Number of subjects: 105
Study: 29435853

Group type: EXPERIMENTAL
Intervention: pCR (pathological complete response)
Number of subjects: 383

Group type: COMPARATOR
Intervention: non-pCR
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 383
Study: 27322798

Group type: EXPERIMENTAL
Intervention: Pioglitazone, 45 mg/d
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 24799157

Group type: COMPARATOR
Intervention: MOBID-2 pain scale
Number of subjects: 352
Study: 22137494

Group type: EXPERIMENTAL
Intervention: Estriol (2 mg/day for 8 weeks)
Number of subjects: 12